Article (Published version) (632 Kb) - 
Limited access to UNIGE
Highlights
Scientific Article
unige:76340 
 |
Treating pulmonary hypertension in pediatrics |
|
| Authors | ||
| Published in | Expert Opinion on Pharmacotherapy. 2015, vol. 16, no. 5, p. 711-726 | |
| Abstract | Pulmonary hypertension is a hemodynamic condition occurring rarely in pediatrics. Nevertheless, it is associated with significant morbidity and mortality. When characterized by progressive pulmonary vascular structural changes, the disease is called pulmonary arterial hypertension (PAH). It results in increased pulmonary vascular resistance and eventual right ventricular failure. In the vast majority of cases, pediatric PAH is idiopathic or associated with congenital heart disease, and, contrary to adult PAH, is rarely associated with connective tissue, portal hypertension, HIV infection or thromboembolic disease. | |
| Keywords | Child — Drug Therapy, Combination — Endothelin Receptor Antagonists/therapeutic use — Epoprostenol/analogs & derivatives/therapeutic use — HIV Infections — Humans — Hypertension, Pulmonary/classification/drug therapy — Phosphodiesterase 5 Inhibitors/therapeutic use — Quality of Life | |
| Identifiers | PMID: 25665593 | |
| Full text | ||
| Structures | ||
| Research group | L'hypertension pulmonaire (pédiatrie) (228) | |
| Citation (ISO format) | LADOR, Frédéric, SEKARSKI, Nicole, BEGHETTI, Maurice. Treating pulmonary hypertension in pediatrics. In: Expert Opinion on Pharmacotherapy, 2015, vol. 16, n° 5, p. 711-726. doi: 10.1517/14656566.2015.1013937 https://archive-ouverte.unige.ch/unige:76340 |
346 hits 
1 download 
Contact an author
Update